, Volume 223, Issue 1, pp 1–15

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens

  • Chad J. Reissig
  • Lawrence P. Carter
  • Matthew W. Johnson
  • Miriam Z. Mintzer
  • Margaret A. Klinedinst
  • Roland R. Griffiths
Original Investigation



Although reports of dextromethorphan (DXM) abuse have increased recently, few studies have examined the effects of high doses of DXM.


This study in humans evaluated the effects of supratherapeutic doses of DXM and triazolam.


Single, acute oral doses of DXM (100, 200, 300, 400, 500, 600, 700, and 800 mg/70 kg), triazolam (0.25 and 0.5 mg/70 kg), and placebo were administered to 12 healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Subjective, behavioral, and physiological effects were assessed repeatedly after drug administration for 6 h.


Triazolam produced dose-related increases in subject-rated sedation, observer-rated sedation, and behavioral impairment. DXM produced a profile of dose-related physiological and subjective effects differing from triazolam. DXM effects included increases in blood pressure, heart rate, and emesis; increases in observer-rated effects typical of classic hallucinogens (e.g., distance from reality, visual effects with eyes open and closed, joy, anxiety); and participant ratings of stimulation (e.g., jittery, nervous), somatic effects (e.g., tingling, headache), perceptual changes, end-of-session drug liking, and mystical-type experience. After 400 mg/70 kg DXM, 11 of 12 participants indicated on a pharmacological class questionnaire that they thought they had received a classic hallucinogen (e.g., psilocybin). Drug effects resolved without significant adverse effects by the end of the session. In a 1-month follow-up, volunteers attributed increased spirituality and positive changes in attitudes, moods, and behavior to the session experiences.


High doses of DXM produced effects distinct from triazolam and had characteristics that were similar to the classic hallucinogen psilocybin.


Dextromethorphan Triazolam Dose effects Hallucinogen Psychedelic Entheogen Drug abuse Subjective effects Mystical experience Humans 

Supplementary material

213_2012_2680_MOESM1_ESM.doc (90 kb)
ESM 1(DOC 89.5 kb)


  1. Addy PH (2012) Acute and post-acute behavioral and psychological effects of Salvinorin A in humans. Psychopharmacology (Berl) 220:195–204CrossRefGoogle Scholar
  2. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23SPubMedGoogle Scholar
  3. Banken JA, Foster H (2008) Dextromethorphan. Ann N Y Acad Sci 1139:402–411PubMedCrossRefGoogle Scholar
  4. Barnhart JW (1980) The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 55:43–48PubMedCrossRefGoogle Scholar
  5. Bem JL, Peck R (1992) Dextromethorphan. An overview of safety issues. Drug Saf 7:190–199PubMedCrossRefGoogle Scholar
  6. Bobo WV, Miller SC, Martin BD (2005) The abuse liability of dextromethorphan among adolescents: a review. J Child Adolesc Subst Abuse 14(4):55–75CrossRefGoogle Scholar
  7. Boyer EW (2004) Dextromethorphan abuse. Pediatr Emerg Care 20:858–863PubMedCrossRefGoogle Scholar
  8. Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson IB (2006) Dextromethorphan abuse in adolescence: an increasing trend: 1999–2004. Arch Pediatr Adolesc Med 160:1217–1222PubMedCrossRefGoogle Scholar
  9. Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31:2537–2551PubMedCrossRefGoogle Scholar
  10. Carter LP, Griffiths RR, Mintzer MZ (2009) Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 206:141–154CrossRefGoogle Scholar
  11. Church J (1990) Dextromethorphan, dysphoria and NMDA receptors. Neuromodulatory effects of dextromethorphan: role of NMDA receptors in responses. Trends Pharmacol Sci 11:146–147PubMedCrossRefGoogle Scholar
  12. Church J, Sawyer D, McLarnon JG (1994) Interactions of dextromethorphan with the N-methyl-D-aspartate receptor-channel complex: single channel recordings. Brain Res 666:189–194PubMedCrossRefGoogle Scholar
  13. Falck R, Li L, Carlson R, Wang J (2006) The prevalence of dextromethorphan abuse among high school students. Pediatrics 118:2267–2269Google Scholar
  14. Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17–33PubMedCrossRefGoogle Scholar
  15. Forrester MB (2011) Dextromethorphan abuse in Texas, 2000–2009. J Addict Dis 30:243–247PubMedCrossRefGoogle Scholar
  16. Franklin PH, Murray TF (1992) High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol 41:134–146PubMedGoogle Scholar
  17. Fribourg M, Moreno JL, Holloway T et al (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011–1023PubMedCrossRefGoogle Scholar
  18. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41–50CrossRefGoogle Scholar
  19. Griffiths RR, Johnson MW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(Suppl 9):31–41PubMedGoogle Scholar
  20. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268–28Google Scholar
  21. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649–665CrossRefGoogle Scholar
  22. Holtzman SG (1982) Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology (Berl) 77:295–300CrossRefGoogle Scholar
  23. Holtzman SG (1994) Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology (Berl) 116:249–254CrossRefGoogle Scholar
  24. Hood RW Jr, Hill PC, Spilka B (2009) The psychology of religion: an empirical approach, 4th edn. Guilford, New YorkGoogle Scholar
  25. Johanson CE, Kilbey M, Gatchalian K, Tancer M (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27–36PubMedCrossRefGoogle Scholar
  26. Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–620PubMedCrossRefGoogle Scholar
  27. Lofwall MR, Griffiths RR, Mintzer MZ (2006) Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 14:439–449PubMedCrossRefGoogle Scholar
  28. Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39Google Scholar
  29. Mintzer MZ, Griffiths RR (2005) An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol 16:579–584PubMedCrossRefGoogle Scholar
  30. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101–106PubMedCrossRefGoogle Scholar
  31. Mumford GK, Rush CR, Griffiths RR (1995) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272:570–580PubMedGoogle Scholar
  32. Murray TF, Leid ME (1984) Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci 34:1899–1911PubMedCrossRefGoogle Scholar
  33. Newell KA, Zavitsanou K, Huang XF (2007) Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J Neural Transm 114:995–1001PubMedCrossRefGoogle Scholar
  34. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181PubMedCrossRefGoogle Scholar
  35. Nicholson KL, Hayes BA, Balster RL (1999) Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 146:49–59CrossRefGoogle Scholar
  36. Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149–162PubMedGoogle Scholar
  37. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239–1258PubMedCrossRefGoogle Scholar
  38. Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62:215–223PubMedCrossRefGoogle Scholar
  39. Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1–10CrossRefGoogle Scholar
  40. Romanelli F, Smith KM (2009) Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc 49:e20–e25CrossRefGoogle Scholar
  41. Rush CR, Frey JM, Griffiths RR (1999) Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 145:39–51CrossRefGoogle Scholar
  42. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618–624PubMedCrossRefGoogle Scholar
  43. Schutz CG, Soyka M (2000) Dextromethorphan challenge in alcohol-dependent patients and controls. Arch Gen Psychiatry 57:291–292PubMedCrossRefGoogle Scholar
  44. Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol 182:313–333PubMedCrossRefGoogle Scholar
  45. Soyka M, Bondy B, Eisenburg B, Schutz CG (2000) NMDA receptor challenge with dextromethorphan—subjective response, neuroendocrinological findings and possible clinical implications. J Neural Transm 107:701–714PubMedCrossRefGoogle Scholar
  46. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose–response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108PubMedCrossRefGoogle Scholar
  47. Tancer ME, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97–101PubMedCrossRefGoogle Scholar
  48. Tancer M, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33–44PubMedCrossRefGoogle Scholar
  49. Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7–14Google Scholar
  50. Vengurlekar SS, Heitkamp J, McCush F, Velagaleti PR, Brisson JH, Bramer SL (2002) A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine—application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal 30:113–124PubMedCrossRefGoogle Scholar
  51. Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651PubMedCrossRefGoogle Scholar
  52. Werling LL, Keller A, Frank JG, Nuwayhid SJ (2007) A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol 207:248–257PubMedCrossRefGoogle Scholar
  53. Wilson MD, Ferguson RW, Mazer ME, Litovitz TL (2011) Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000–2010. Clin Toxicol (Phila) 49:409–415CrossRefGoogle Scholar
  54. Winter JC, Doat M, Rabin RA (2000) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337–344PubMedCrossRefGoogle Scholar
  55. Winter JC, Eckler JR, Rice KC, Rabin RA (2005) Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram. Pharmacol Biochem Behav 81:694–700PubMedCrossRefGoogle Scholar
  56. Wolfinger R, Chang M (1995) Comparing the SAS GLM and MIXED procedures for repeated measurements analysis. SUGI Proc 1995:1–11Google Scholar
  57. Young AM, Herling S, Winger GD, Woods JH (1981) Comparison of discriminative and reinforcing effects of ketamine and related compounds in the rhesus monkey. NIDA Res Monogr 34:173–179PubMedGoogle Scholar
  58. Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM (1998) Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 18:332–337PubMedCrossRefGoogle Scholar
  59. Zawertailo LA, Tyndale RF, Busto U, Sellers EM (2010) Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol 25:71–79PubMedCrossRefGoogle Scholar
  60. Ziaee V, Akbari HE, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K (2005) Side effects of dextromethorphan abuse, a case series. Addict Behav 30:1607–1613PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Chad J. Reissig
    • 1
  • Lawrence P. Carter
    • 3
  • Matthew W. Johnson
    • 1
  • Miriam Z. Mintzer
    • 1
  • Margaret A. Klinedinst
    • 1
  • Roland R. Griffiths
    • 1
    • 2
  1. 1.Department of Psychiatry and Behavioral SciencesJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of NeuroscienceJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of Pharmacology and ToxicologyUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations